Skip to main content

Mast Cell Activation Syndrome

Question for Department of Health and Social Care

UIN 129385, tabled on 23 February 2018

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of allowing the use of off-label medications in the treatment of Mast Cell Activation Syndrome.

Answered on

28 February 2018

We have made no such assessment. Prescribers are able to use medicinal products outside their licensed indications where they are satisfied that they best meet the individual clinical needs of their patient. This is part and parcel of normal clinical practice.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.